Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Postmarketing Trial
Sort By
Newest First
1 / 1
1 / 1
Postmarketing Trial
FDA Responds to Safety Signal Reported in Required Postmarketing Trial for Xeljanz
U.S. Food & Drug Administration
PR-M02-19-NI-068
Feb 28, 2019
